Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cross-Reactive Material 197 (CRM197)
- Target
- CRM197
- Molecular classification
- Toxin (mutated), Carrier Protein
01
Overview
Cross-Reactive Material 197 (CRM197) is a non-toxic mutant of diphtheria toxin used as a carrier protein in conjugate vaccines. The mutation (G52E) abolishes ADP-ribosyltransferase activity, eliminating toxicity, while preserving the protein's structure and lysine residues for conjugation. It enhances the immunogenicity of polysaccharides and haptens, eliciting stronger immune responses. CRM197 is also explored as an HB-EGF inhibitor and for targeted drug delivery.
- Other names
- Diphtheria CRM197Diphtheria Toxin CRM197Diphtheria mutant protein
02
Mechanism of action
Acts as a carrier to present weakly immunogenic antigens to the immune system, facilitating T-cell help and enhanced antibody production. Can also inhibit HB-EGF signaling.
03
Biological functions
Vaccine carrierEnhances immunogenicityHB-EGF inhibitorTargeted drug delivery (potential)
04
Disease associations
Infection (vaccine prevention)Cancer (potential HB-EGF inhibition)
05
Safety considerations
Potential for carrier-induced suppression (less than toxoid)Manufacturing process considerations to maintain structure and function
Beyond the preview
Go deeper on Cross-Reactive Material 197 (CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cross-Reactive Material 197 (CRM197).